Pharma
$250 Million Bet on Innovation: Zymeworks Secures Major Royalty-Backed Funding Deal
Zymeworks secures $250 million royalty-backed financing from Royalty Pharma, strengthening its oncology pipeline and extending its runway beyond 2028.
E
Editorial Desk
3/2/2026, 8:07:32 PM
